Pharma R&D spend increases by 40%February 2013
Pharmaceutical industry-led R&D on developing new and improved vaccines to tackle neglected diseases have increased in number by 40%, according to the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) status report for 2012. Last year’s 132 live projects focus on a range of diseases prioritised by the World Health Organization’s Special Programme for Research & Training in Tropical Diseases (TDR) and include tuberculosis, malaria, human African trypanosomiasis (sleeping sickness), leishmaniasis, dengue, onchocerciasis (River blindness), American trypanosomiasis (Chagas disease) and leprosy. Their target is to help build capacity and address diseases that disproportionately affect people in low- and middle-income countries.
Already a member? click here to login